Identification of DDIT4 as a potential prognostic marker associated with chemotherapeutic and immunotherapeutic response in triple-negative breast cancer

Chen, Xuanzhao; Li, Zeyan; Liang, Meihua; Zhang, Ziyang; Zhu, Daiyin; Lin, Biyun; Zhou, Renyu; Lu, Yuanzhi

doi:10.1186/s12957-023-03078-7

Cited by 3 publications

(1 citation statement)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DNA damage inducible transcript 4 (DDIT4), an inhibitor of the mammalian target of rapamycin (mTOR), is expressed in response to various cellular stresses 41 . Research indicates that in various malignancies, DDIT4 is involved in tumorigenesis and influences patient survival 42 – 44 . Studies have confirmed that high DDIT4 expression may be a poor prognostic indicator for AML 45 .…”

Section: Discussionmentioning

confidence: 99%

NET-related gene signature for predicting AML prognosis

Wang,

Ding

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Acute Myeloid Leukemia (AML) is a malignant blood cancer with a high mortality rate. Neutrophil extracellular traps (NETs) influence various tumor outcomes. However, NET-related genes (NRGs) in AML had not yet received much attention. This study focuses on the role of NRGs in AML and their interaction with the immunological microenvironment. The gene expression and clinical data of patients with AML were downloaded from the TCGA-LAML and GEO cohorts. We identified 148 NRGs through the published article. Univariate Cox regression was used to analyze the association of NRGs with overall survival (OS). The least absolute shrinkage and selection operator were utilized to assess the predictive efficacy of NRGs. Kaplan–Meier plots visualized survival estimates. ROC curves assessed the prognostic value of NRG-based features. A nomogram, integrating clinical information and prognostic scores of patients, was constructed using multivariate logistic regression and Cox proportional hazards regression models. Twenty-seven NRGs were found to significantly impact patient OS. Six NRGs—CFTR, ENO1, PARVB, DDIT4, MPO, LDLR—were notable for their strong predictive ability regarding patient survival. The ROC values for 1-, 3-, and 5-year survival rates were 0.794, 0.781, and 0.911, respectively. In the training set (TCGA-LAML), patients in the high NRG risk group showed a poorer prognosis (p < 0.001), which was validated in two external datasets (GSE71014 and GSE106291). The 6-NRG signature and corresponding nomograms exhibit superior predictive accuracy, offering insights for pre-immune response evaluation and guiding future immuno-oncology treatments and drug selection for AML patients.

show abstract

Section: Discussionmentioning

confidence: 99%

NET-related gene signature for predicting AML prognosis

Wang,

Ding

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

Ferroptosis-related gene signature for predicting prognosis and identifying potential therapeutic drug in EGFR wild-type lung adenocarcinoma

Zhang,

Wu,

Yang

et al. 2024

Commun Biol

View full text Add to dashboard Cite

Epidermal growth factor receptor wild type lung adenocarcinoma (EGFR WT LUAD) still has limited treatment options and unsatisfactory clinical outcomes. Ferroptosis, as a form of cell death, has been reported to play a dual role in regulating tumor cell survival. In this study, we constructed a 3-ferroptosis-gene signature, FeSig, and verified its accuracy and efficacy in predicting EGFR WT LUAD prognosis at both the RNA and protein levels. Patients with higher FeSig scores were found to have worse clinical outcomes. Additionally, we explored the relationship between FeSig and tumor microenvironment, revealing that enhanced interactions between fibroblasts and tumor cells in FeSig high patients causing tumor resistance to ferroptosis. To address this challenge, we screened potential drugs from NCI-60 (The US National Cancer Institute 60 human tumour cell line anticancer drug screen) and Connectivity map database, ultimately identifying 6-mercatopurine (6-MP) as a promising candidate. Both in vitro and in vivo experiments demonstrated its efficacy in treating FeSig high EGFR WT LUAD tumor models. In summary, we develop a novel FeSig for predicting prognosis and guiding drug application.

show abstract

Role of ENO1 and its targeted therapy in tumors

Li,

Liu,

2024

J Transl Med

View full text Add to dashboard Cite

three highly conserved isoforms of enolase in mammals are α-enolase (ENO1), β-enolase (ENO3), and γ-enolase (ENO2). Among them, ENO1 accounts for 90% of the glycolytic pathway's cytosolic enolase activity [3]. Furthermore, ENO1 overexpression is associated with poor prognosis in many types of cancer [4]. ENO2, predominantly localized in the cytoplasm of neurons and neuroendocrine cells, has been identified as a serum marker for tumors of neuronal lineage, such as glioblastoma (GBM) and medulloblastoma [5,6]. Recent studies, however, have revealed that ENO2 is not only highly expressed in neurological tumors but also plays a critical role in the progression of other malignancies, including lung adenocarcinoma (LUAD) and breast cancer. A multiomic analysis demonstrated that 3D tumor spheroid growth implies the overexpression of ENO2 and another glycolytic enzyme, ALDOC, concomitant with the enhanced consumption of glucose and fructose and the enhanced production of lactate, in lung and breast cancer cell lines in different nutrient environmental conditions [7]. ENO3 is predominantly expressed in muscle tissue, with studies indicating that 86% of rhabdomyosarcomas test positive

show abstract

Identification of DDIT4 as a potential prognostic marker associated with chemotherapeutic and immunotherapeutic response in triple-negative breast cancer

Cited by 3 publications

References 56 publications

NET-related gene signature for predicting AML prognosis

NET-related gene signature for predicting AML prognosis

Ferroptosis-related gene signature for predicting prognosis and identifying potential therapeutic drug in EGFR wild-type lung adenocarcinoma

Role of ENO1 and its targeted therapy in tumors

Contact Info

Product

Resources

About